Yale Cancer Center and our partner, Smilow Cancer Hospital, acknowledge the seven American Society of Clinical Oncology (ASCO) and National Comprehensive Cancer Network (NCCN) evidence-based quality guidelines for breast and colorectal cancers. The latest performance data for breast center is listed below.
|Breast Measures||Expected Estimated Performance Rates (percentage)||Yale Performance 2017||Yale Performance 2018||Yale Performance 2019|
|Tamoxifen or third generation aromotase inhibitor is recommended or administered within 1 year (365 days) of diagnosis for women with AJCC T1cN0M0 or stage IB-III hormone receptor positive breast cancer (Accountability)||90%||92.3||94.9||90.8|
|Radiation therapy is recommended or administered following any mastectomy within 1 year (365 days) of diagnosis of breast cancer for women with >= 4 positive regional lymph nodes (Accountability)||90%||84.2*||100||100|
|Radiation is administered within 1 year (365 days) of diagnosis for women under the age of 70 receiving breast conservation surgery for breast cancer (Accountability)||90%||93||95.1||94|
|Combination chemotherapy is considered or administered within 4 months (120 days) of diagnosis for women under 70 with AJCC T1cN0, or stage IB - III hormone receptor negative breast cancer (Accountability)||90%||90.9||96.5||100|
*Total of 3/19 patients received radiation, but occurred more than 1 year after diagnosis (Reasons: (a) 2 patients the decision was to add more chemo s/p neoadjuvant followed by mastectomy due to disease extension; (b) XRT delayed as a patient required an ostomy for an unrelated condition).